Methicillin-resistant Staphylococcus aureus: An evolutionary, epidemiologic, and therapeutic odyssey

Clinical Infectious Diseases

Volumn 40, Issue 4, 2005, Pages 562-573

  Deresinski, Stan ^a,b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; 7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; 7BETA [2 (5 AMINO 1,2,4 THIADIAZOL 3 YL) 2 ETHOXYIMINOACETAMIDO] 3 [(1 METHYLAMINOPROPYL 1H IMIDAZO[4,5 B]PYRIDINIUM 4 YL)METHYL] 3 CEPHEM 4 CARBOXYLIC ACID; ALTASTAPH; ANTIBIOTIC AGENT; AUREXIS; AUROGRAB; BETA LACTAM ANTIBIOTIC; BMS 247243; BYSX A110; CADMIUM; CB 181963; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; DW 286; GATIFLOXACIN; GLYCOPEPTIDE; GLYCYLGLYCINE; LEVOFLOXACIN; LINEZOLID; ME 1036; MINOCYCLINE; MOXIFLOXACIN; ORITAVANCIN; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SM 197436; SM 232721; SM 232724; STAPHVAX; TELAVANCIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TOPICAL AGENT; TRICLOSAN; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VERONATE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; CLINICAL TRIAL; COMMUNICABLE DISEASE; DRUG CHOICE; DRUG COST; ENDOCARDITIS; EVOLUTION; HEALTH CARE FACILITY; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COMMUNITY-ACQUIRED INFECTIONS; EPIDEMIOLOGY, MOLECULAR; EVOLUTION, MOLECULAR; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 13944274479     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427701     Document Type: Review

References (163)

1. Rammelkamp M. Resistances of Staphylococcus aureus to the action of penicillin. Proc Roy Soc Exper Biol Med 1942;51:386-9.
2. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178-82.
3. Jevons MP. "Celbenin"-resistant staphylococci. Br Med J 1961; 1: 124-5.
4. Diekema DJ, BootsMiller BJ, Vaughn TE, et al. Antimicrobial resistance trends and outbreak frequency in United States Hospitals. Clin Infect Dis 2004; 38:78-85.
5. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance System report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31:481-98.
6. Tacconelli E, Venkataraman L, De Girolami PC, D'Agata EM. Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare- associated strains. J Antimicrob Chemother 2004; 53: 474-9.
7. Charlesbois ED, Pedreau-Remington F, Kreiswierth B, et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004; 39:47-54.
8. Calfee DP, Durbin LJ, Germanson TP, et al. Spread of methicillin- resistant Staphylococcus aureus (MRSA) among household contacts of individuals with nosocomially acquired MRSA. Infect Control Hosp Epidemiol 2003; 24:422-6.
9. Centers for Disease Control and Prevention. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus infections-Los Angeles County, 2002-2003. MMWR Morb Mortal Wkly Rep 2003; 52:88.
10. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections in correctional facilities-Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003; 52:992-6.
11. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976-84.
12. Hulten KG, Mason EO, Versalovic J, et al. Comparison of community-acquired and health-care associated S. aureus by antibiotic susceptibility and molecular methods [abstract 485]. In: Program and abstracts of the 41st Annual Meeting of the Infectious Disease Society of America. Alexandria, VA: Infectious Diseases Society of America, 2003.
13. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001; 286:1201-5.
14. Carleton H, Charlesbois E, Perdreau-Remington F. Dramatic increase of staphylococcal chromosomal cassette mec (SCCmec) type IV in both a nosocomial and community setting [abstract C2-983]. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2003.
15. Zinderman CE. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis 2004; 10: 941-4.
16. Shahin R, Johnson I, Jamieson F, et al. Methicillin-resistant Staphylococcus aureus carriage in a childcare center following a case of disease. Arch Pediatr Adolesc Med 1999; 153:864-8.
17. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 2003; 52:793-5.
18. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999; 48:707-10.
19. Saiman L, O'Keefe M, Graham PL 3rd, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003; 37:1313-9.
20. O'Brien FG, Pearman M, Gracey T, et al. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 1999; 37:2858-62.
21. Donnio PY, Preney L, Gautier-Lerestif AL, et al. Changes in staphylococcal cassette chromosome type and antibiotic resistance profile in methicillin-resistant Staphylococcus aureus isolates from a French hospital over an 11 year period. J Antimicrob Chemother 2004; 53: 808-13.
22. Hartman A, Tomasz B. Altered penicillin-binding proteins in methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother 1981; 19:726-35.
23. Fuda C, Suvorov M, Vakulenko SB, Mobashery S. The basis for resistance to β-lacatm antibiotics by penicillin-binding protein 2a (PBP2a) of methicillin-resistant Staphylococcus aureus. J Biol Chem 2004; 279:40802-6.
24. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, Staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44:1549-55.
25. Hiramatsu K. Elucidation of the mechanism of antibiotic resistance acquisition of methicillin-resistant Staphylococcus aureus (MRSA) and determination of its whole geneome nucleotide sequence. JMAJ 2004; 47:153-9.
26. Robinson DA, Enright MC. Multilocus sequence typing and the evolution of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2004; 10:92-7.
27. Zhang HZ, Hackbarth CJ, Chansky KM, Chambers HF. A proteolytic transmembrane signaling pathway and resistance to β-lactams in staphylococci. Science 2001; 291:1962-5.
28. Archer GL, Bosilevac JM. Signaling antibiotic resistance in staphylococci. Science 2001; 291:1915-6.
29. Tomasz A, Nachman S, Leaf H. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1991; 35:124-9.
30. de Lencastre H, de Jonge BL, Matthews PR, Tomasz A. Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother 1994; 33:7-24.
31. Enright MC, Day NP, Davies CE, et al. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptibile clones of Staphylococcus aureus. J Clin Microbiol 2000; 38: 1008-15.
32. Ito T, Katayama Y, Asada K, et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45:1323-36.
33. Ito T, Ma XX, TakeuchiF, et al. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 2004;48:2637-51.
34. Hindler J. Staphylococcus inducible clindamycin resistance: clindamycin induction test for staphylococcal spp. Available at: http:// www.phppo.cdc.gov/dls/master/default.asp. Accessed 5 January 2005.
35. Ma XX, Ito C, Tiensasitorn C, Jamklang P, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46:1147-52.
36. O'Brien FG, Lim TT, Chong FN, et al. Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J Clin Microbiol 2004; 42:3185-90.
37. Enright MC, Robinson DA, Randle G, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A 2002; 99:7687-92.
38. Song MD, Wachi M, Doi M, et al. Evolution of an inducible penicillin-target protein in methicillin-resistant Staphylococcus aureus by gene fusion. FEBS Lett 1987; 221:167-71.
39. Wu SW, DE Lencastre H, Tomasz A. Recruitment of the mecA gene homologue of Staphylococcus sciuri into a resistance determinant and expression of the resistant phenotype in Staphylococcus aureus. J Bacteriol 2001; 183:2417-24.
40. Wisplinghoff H, Rosato AE, Enright MC, et al. Related clones containing SCCmec type IV predominate among clinically significant Staphylococcus epidermidis isolates. Antimicrob Agents Chemother 2003; 47:3574-9.
41. Okuma K, Iakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40:4289-94.
42. Baba T, Takeuchi F, Kuroda M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359:1819-27.
43. Roberts RB, Tennenberg AM, Eisner W, et al. Outbreak in a New York City teaching hospital burn center caused by the Iberian epidemic clone of MRSA. Microb Drug Resist 1998; 4:175-83.
44. Perdreau-Remington F, Carleton HA, Etorma J, et al. Alarming prevalence of community-acquired methicillin resistant Staphylococcus aureus (CA-MRSA) in hospitalized patients [abstract K-1859a]. In: Program and abstracts of the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2004.
45. Aires de Sousa M, de Lencastre H. Evolution of sporadic isolates of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals and their similarities to isolates of community-acquired MRSA. J Clin Microbiol 2003;41:3806-15.
46. Sutherland R, Rolinson GN. Characteristics of methicillin-resistant staphylococci. J Bacteriol 1964; 87:887-99.
47. Ender M, McCallum N, Adhikari R, Berger-Bächi B. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48:2295-7.
48. Panton PN, Valentine FCO. Staphylococcal toxin. Lancet 1932; 222: 506-8.
49. Szmiegielski S, Prevost G, Monteil H, et al. Leukocidal toxins of staphylococci. Zentralbl Bakteriol 1999; 289:185-201.
50. Kaneko J, Kamio Y. Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem 2004; 68: 981-1003.
51. Kaneko J, Kimura T, Kawakami Y, et al. Panton-Valentine leukocidin genes in phage-like particles isolated from mitomycin C-treated Staphylococcus aureus V8 (ATCC 49775). Biosci Biotechnol Biochem 1997;61:1960-2.
52. Kaneko J, Kimura T, Narita S, et al. Complete nucleotide sequence and molecular characterization of the temprate Staphylococcal bacteriophage øPVL carrying Panton-Valentine leukocidin genes. Gene 1998; 215:57-67.
53. Ward PD, Turner WH. Identification of Staphylococcal Panton-Valentine leukocidin as a potent dermonecrotic toxin. Infect Immun 1980; 28:393-7.
54. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002; 359:753-9.
55. Pearman JW, Grubb WB. Emerging strains of multiresistant methicillin-resistant Staphylococcus aureus threaten success of screening policy. APUA Newsletter 1993; 11:1-8.
56. Udo EE, Pearman JW, Grubb WB. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1994; 26:157-65.
57. Pan ES, Charlesbois ED, Auerswald C, et al. Homeless youth at increased risk for methicillin-resistant Staphylococcus aureus (MRSA) colonization [abstract 255]. In: Program and abstracts of the 41st Annual Meeting of the Infectious Disease Society of America. Alexandria, VA: Infectious Diseases Society of America, 2003.
58. Lodise TP, McKinnon PS, Levine DP, Rybak MJ. Predictors of mortality and impact of initial therapy on outcomes in intravenous drug users (IVDU) with Staphylococcus aureus (SA) infective endocarditis (IE) [abstract L-765]. In Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Alexandria, VA: Infectious Diseases Society of America, 2002.
59. McKinnon PS, Lodise TP Jr, Rybak MJ. Impact of initial treatment with vancomycin versus a beta-lactam on outcomes and costs of methicillin-susceptible Staphylococcus aureus bacteremia (MSSAB) [abstract 579]. In: Program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America, 24-27 October, 2002, Chicago, Illinois.
60. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficiacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-402.
61. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47:3040-5.
62. Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediated Staphylococcus aureus. Clin Infect Dis 2004; 38:448-51.
63. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902.
64. Blondeau JM, Sanche SE. Quinupristin/dalfopristin. Expert Opin Pharmacother 2002; 3:1341-64.
65. Livermore DM. Antibiotic resistance in staphylococci. Int J Antimicrob Agents 2000; 16(Suppl 1):S3-10.
66. Fagon JY, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/ dalfopristin versus vancomycin. Am J Resp Crit Care Med 2000; 161:753-62.
67. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-90.
68. Yogev R, Patterson LE, Kaplan SL, et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 2003;22 (Suppl 9):S172-7.
69. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:343-6.
70. Wunderink RG, Rello J, Cammarata SK. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
71. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:2538-44.
72. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of gram-positive infections. Expert Opin Investig Drugs 2004; 13:1159-69.
73. Cubist Pharmaceuticals. Clinical study report: protocol DAP-RCC-9804. Available at: http://www.fda.gov/cder/foi/nda/2003/21-572_cubicin.htm. Accessed 21 January 2003.
74. Trzcinski K, Cooper BS, Hyrniewicz W, Dowson CG. Expression of resistance to strains of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2000; 45:763-70.
75. Schmitz FJ, Krey A, Sadurski R, et al. Resistance to tetracycline and distribution of tetracycline resistance genes in European Staphylococcus aureus isolates. J Antimicrob Chemother 2001; 47:239-46.
76. Nicolau DP, Freeman CD, Nightingale CH, et al. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxaculin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1994; 38:1515-8.
77. Ruhe JJ, Monson TP. Use of tetracyclines for infections caused by methicillin-resistant Staphylococcus aureus [abstract 516]. In: Program and abstracts of the 42nd Annual Meeting Meeting of the Infectious Disease Society of America, 30 September-3 October, 2004, Boston, Massachusetts.
78. de Gorgolas M, Aviles P, Verdejo C, Fernandez Guerrero ML. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin- resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 1995; 39:953-7.
79. Scheid WM, Keeley JM, Field MR, Brodeur JP. Co-trimoxazole versus nafcillin in the therapy of experimental meningitis due to Staphylococcus aureus. J Antimicrob Chemother 1987; 19:647-58.
80. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390-98.
81. Adra M, Lawrence KR. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004; 38:338-41.
82. Hershow RC, Khayr WF, Schreckenberger PC. Ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: associated factors and resistance to other antibiotics. Am J Ther 1998; 5:213-20.
83. Limoncu MH, Ermertcan S, Cetin CB, et al. Emergence of phenotypic resistance to ciprofloxacin and levofloxacin in methicillin-resistant and methicillin-sensitive Staphylococcus aureus strains. Int J Antimicrob Agents 2003; 21:420-4.
84. Venezia RA, Domaracki BE, Evans AM, et al. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother 2001; 48:375-81.
85. Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415-22.
86. Shopsin B, Zhao X, Kreiswirth BN, et al. Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int J Antimicrob Agents 2004; 24:32-4.
87. Firsov AA, Vostrov SN, Lubenko IY, et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1604-13.
88. Firsov AA, Vostrov SN, Lubenko IY, et al. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int J Antimicrob Agents 2004; 23:451-6.
89. Martinez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593-8.
90. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530-4.
91. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257-60.
92. Schreckenberger PC, Ilendo E, Ristow KL. Incidence of constitutive and inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci in a community and a tertiary care hospital. J Clin Microbiol 2004; 42:2777-9.
93. Centers for Disease Control and Prevention. Testing/reporting protocols: Staphylococcus-inducible clindamycin resistance. Available at: http://www.phppo.cdc.gov/dls/master/default.asp. 2003. Accessed 6 January 2005.
94. Schmilz FJ, Fluit AC, Hafner D, et al. Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2000; 44:3229-31.
95. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA. Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. The Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Int I Antimicrob Agents 2004; 23: 577-81.
96. Brenwald NP, Fraise AP. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 2003; 55:141-4.
97. Fan F, Yan K, Wallis NG, et al. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:3343-7.
98. Lee M, Rios AM, Fonseca Aten M, et al. Management of cutaneous abscesses due to community-acquired MRSA [abstract G-1541]. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2003.
99. Guay DR. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 2004; 24:58-68.
100. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003; 26:511-32.
101. Giamarellou H, O'Riordan W, Harris H, Owen S, Porter S, Loutit J. Phase 3 trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI) [abstract L-739a]. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2003.
102. Fellerly GJ, Ong C, Bhavnani SM, et al. Characterization of oritavancin (ORI) pharmacokinetics (PK) in plasma and blister fluid in normal healthy volunteers [abstract A-18]. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2003.
103. Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003; 37:1298-303.
104. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother 2004; 53:797-803.
105. Clinical trial: telavancin (TD 6424, arbelic) for treatment of uncomplicated Staphylococcus aureus bacteremia. Availabe at: http://www .clinicaltrials.gov/ct/gui/show/NCT00062647?amp;order=7.Accessed 6 January 2005.
106. Duchin K. Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects [abstract 902]. J Thromb Haemost 2003; 1(Suppl 1):1027.
107. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004; 48:3043-50.
108. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49:201-9.
109. Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53:592-9.
110. Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26:704-14.
111. Glinka TW. Novel cephalosporins for the treatment of MRSA infections. Curr Opin Investig Drugs 2002; 3:206-17.
112. Fung-Tome JC, Clark J, Minassian B, et al. In vitro activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci. Antimicrob Agents Chemother 2002; 46: 971-6.
113. Malouin F. Blais J, Chamberland S, et al. RWJ-54428(MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP2a, and stability to staphylococcal beta-lactamases. Antimicrob Agents Chemother 2003; 47:658-64.
114. Huang V, Brown WJ, Rybak MJ. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci. Antimicrob Agents Chemother 2004; 48: 2719-23.
115. Azoulay-Dupuis E, Bedos JP, Mohler J, et al. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob Agents Chemother 2004; 48: 1105-11.
116. Entenza JM, Hohl P, Heinze-Krauss I, et al. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother 2002; 46:171-7.
117. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002; 50: 915-32.
118. Fujimura T, Yamano Y, Yoshida I, et al. In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003; 47:923-31.
119. Kurazono M, Ida T, Yamada K, et al. In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2004; 48:2831-7.
120. Ueda Y, Sunagawa M. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1β-methylcarbapenems with potent activities against multiresistant gram-positive bacteria. Antimicrob Agents Chemother 2003; 47:2471-80.
121. Kim MJ, Yun HJ, Kang JW, et al. In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates. J Antimicrob Chemother 2003; 51: 1011-6.
122. Yun HJ, Min YH, Kang JW, et al. In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic. Antimicrob Agents Chemother 2002; 46:3071-4.
123. Firsov AA, Vostrov SN, Lubenko IY, et al. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 2004; 54:178-86.
124. Champney WS, Tober CL. Evernimicin (SCH27899) inhibits both translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother 2000; 44:1413-7.
125. Belova L, Tenson T, Xiong L, et al. A novel site of antibiotic action in the ribosome: interaction of evernimicin with the large ribosomal subunit. Proc Natl Acad Sci U S A 2001;98:3726-31.
126. Aarestrup FM. Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomycin (SCH 27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin. Microb Drug Resist 1998; 4:137-41.
127. Wichelhaus TA, Schäfer V, Brade V, Böddinghaus B. Differential effect of rpoB mutations on antibiacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. J Antimicrob Chemother 2001; 47:153-6.
128. Locher HH, Schlunegger H, Hartman PG, et al. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob Agents Chemother 1996; 40: 1376-81.
129. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003; 13:4217-21.
130. Hutchinson DK. Oxazolidinone antibacterial agents: a critical review. Curr Top Med Chem 2003;3:1021-42.
131. Hoellman DB, Lin G, Ednie LM, et al. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob Agents Chemother 2003; 47:1148-50.
132. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18:456-62.
133. Hill J, Siedlecki J, Parr I, et al. Synthesis and biological activity of N-acylated ornithine analogues of daptomycin. Bioorg Med Chem Lett 2003; 13:4187-91.
134. Appelbaum P. Antistaphylococcal activity of NVP-PDF713, a new peptide deformylase inhibitor compared with other agents [abstract 902]. J Thromb Haemost 2003;1(Suppl 1):915.
135. Jones RN, Fritsche TR, Sader HS. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-positive clinical isolates. Diagn Microbiol Infect Dis 2004; 49:63-5.
136. Lofland D, Difuntorum S, Waller A, et al. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J Antimicrob Chemother 2004; 53:664-8.
137. Friedrich CL, Moyles D, Beveridge TJ, Hancock RE. Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. Antimicrob Agents Chemother 2000; 44:2086-92.
138. Nibbering PH, Ravensbergen E, Welling MM, et al. Human lactoferrin and peptides derived from its N-terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun 2001; 69: 1469-76.
139. von Eiff C, Kokai-Kun JF, Becker K, Peters G. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. Antimicrob Agents Chemother 2003; 47: 3613-5.
140. Climo MW, Patron RL, Goldstein BP, et al. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother 1998; 42:1355-60.
141. Stark FR, Thornsvard C, Flannery EP, Artenstein MS. Systemic lysostaphin in man-apparent antimicrobial activity in a neutropenic patient. N Engl J Med 1974; 291:239-40.
142. Sulakvelidze A, Alavidze Z, Moriss JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45:649-59.
143. Matsuzaki S, Yasuda M, Nishikawa H. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 2003; 187:613-24.
144. Dell'Acqua G, Giacometti A, Cirioni O. Suppression of drug-resistant staphylococcal infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. J Infect Dis 2004; 190:318-20.
145. Yarwood JM, Schlievert PM. Quorum sensing in Staphylococcus infections. J Clin Invest 2003; 112:1620-5.
146. Lyon GJ, Mayville P, Muir TW, Novick RP. Rational design of a global inhibitor of the virulence response in Staphylococcus aureus, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC. Proc Nad Acad Sci U S A 2000; 97:13330-5.
147. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002:346:491-6.
148. Robbins JB, Scheerson R, Horwith G, et al. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. Am Heart J 2004; 147:593-8.
149. Clinical trial: safety and behavior of S. aureus immune globulin intravenous (human), [altastaph] in patients with S. aureus bacteremia and continuing fever. Available at: http://www.clinicaltrials.gov/ct/gui/ show/NCT00063089?amp;order=5. Accessed 6 January 2005.
150. Safety study of an intravenous Staphylococcus aureus immune globulin (human), [altastaph] in low-birth-weight neonates. Available at: http://www.clinicaltrials.gov/ct/gui/show/NCT00066989?amp;order= 1. Accessed 6 January 2005.
151. Hall AE, Domanski PJ, Patel PR, et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 2003; 71:6864-70.
152. Inhibitex. Product candidates: aurexis. Available at: http://www .inhibitex.com/product/aurexis.asp. Accessed 6 January 2005.
153. Inhibitex. Product candidates: veronate. Available at: http://www .inhibitex.com/product/veronate.asp. Accessed 6 January 2005.
154. Weisman LE. Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient. Curr Opin Infect Dis 2004; 17:237-41.
155. Burnie JP, Matthews RC, Carter T, et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 2000; 68:3200-9.
156. Patti JM. Immunotherapeutics for nosocomial infections. Expert Opin Investig Drugs 2004; 13:673-9.
157. Todd JK. Therapy of toxic shock syndrome. Drugs 1990; 39:856-61.
158. Shupp JW, Jett M, Pontzer CH. Identification of a transcytosis epitope on staphylococcal enterotoxins. Infect Immun 2002; 70:2178-86.
159. Gaudachon V, Cozon G, Vandensch F, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004; 189:346-53.
160. Holden MT, Feil EJ, Lindsay JA, et al. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci U S A 2004; 101: 9786-91.
161. Eguia JM, Chambers HF. Community-acquired methicillin-resistant Staphylococcus aureus: epidemiology and potential virulence factors. Curr Infect Dis Rep 2003; 5:459-66.
162. Cooper BS, Medley GF, Stone SP, et al. Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc Natl Acad Sci U S A 2004; 101:10223-8.
163. Ulrich D, Hochut B, Hentschel U, Hacker J. Genomic islands in pathogenic and environmental microorganisms. Nat Rev Microbiol 2004; 2:414-24.